MARKET

MCRB

MCRB

Seres Therapeutics Inc
NASDAQ
7.08
+0.24
+3.43%
After Hours: 7.08 0 0.00% 17:04 06/26 EDT
OPEN
6.85
PREV CLOSE
6.85
HIGH
7.57
LOW
6.85
VOLUME
301.49K
TURNOVER
--
52 WEEK HIGH
29.98
52 WEEK LOW
5.31
MARKET CAP
68.56M
P/E (TTM)
-1.3950
1D
5D
1M
3M
1Y
5Y
1D
Synopsys, Talen, Home Depot, Seres, Darden Trending With Analysts
TipRanks · 15h ago
Seres Therapeutics To Host July 8 Webcast To Discuss Top-Line Results From A Trial Evaluating SER-155 In Patients With Immune Checkpoint Inhibitor-Related Enterocolitis
Benzinga · 2d ago
Seres Therapeutics to present top-line data from SER-155 trial in immune checkpoint inhibitor-related enterocolitis on July 8 webcast
PUBT · 2d ago
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Benzinga · 4d ago
Seres Therapeutics Price Target Announced at $12.00/Share by HC Wainwright & Co.
Dow Jones · 4d ago
Seres Therapeutics Initiated at Buy by HC Wainwright & Co.
Dow Jones · 4d ago
HC Wainwright & Co. Initiates Coverage On Seres Therapeutics with Buy Rating, Announces Price Target of $12
Benzinga · 4d ago
Seres Therapeutics initiated with a Buy at H.C. Wainwright
TipRanks · 4d ago
More
About MCRB
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.

Webull offers Seres Therapeutics Inc stock information, including NASDAQ: MCRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MCRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MCRB stock methods without spending real money on the virtual paper trading platform.